- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02155075
Evaluation of Real Imaging's 3D Functional Metabolic Imaging and Risk Assessment (MIRA) System
Evaluation of Real Imaging's 3d Functional Metabolic Imaging and Risk Assessment (Mira) System
Three-dimensional functional Metabolic Imaging (3D MIRA) is a new infrared imaging technology using the Real Imager 8 (RI8) developed by Real Imaging. This technology generates 3D metabolic maps of the breast and based on sophisticated machine learning technology, provides objective risk assessment for the presence of malignant tumor in the breast. The procedure is non-invasive, comfortable and does not involve ionizing radiation. It is based on acquiring infrared images of the breast. Those images are processed and analyzed by computers to provide the objective risk assessment.
The technology is intended to be used as a screening tool for breast cancer and emerges as highly useful in women for whom screening mammography is sub-optimal, such as women with dense breast. 3D MIRA is unaffected by breast density and is therefore ideal for evaluating patients with mammographically dense breasts.
The purpose of this clinical study is to assess the ability of this novel technology to detect breast cancer in women.
Study Overview
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Ramat-Gan, Israel, 5262000
- Recruiting
- The Chaim Sheba Medical Center at Tel HaShomer
-
Contact:
- Shelly Curtis
- Phone Number: 972-50-722-4421
- Email: Shelly@realimaging.com
-
Principal Investigator:
- Miri Sklair-Levy, MD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
PHASE 1:
INCLUSION CRITERIA
- Female
- Woman has read, understood and signed the inform consent form
- Age: 30 years and older
- A. Women who are scheduled to undergo routine Mammography and/or US and/or MRI screening OR B. Women summoned for breast biopsy following a suspicious finding in recent screening exam and was graded 4/5 on BI-RADS scale
EXCLUSION CRITERIA:
- Women who have had a Mammography and/or US and/or MRI examination performed on the day of the study prior to MIRA scan
- Women who had undergone mastectomy and/or breast reconstruction
- Women who have had a breast biopsy performed throughout the 6 weeks preceding the study
- Women who have a fever on the day of the MIRA imaging
- Women who are pregnant
- Women who are breast-feeding
- Women with implanted pacemaker/defibrillator, implanted venous access device (portacath) or other implanted devices in the chest area
- Women who are unable to read, understand and execute written informed consent
- Women who are currently undergoing chemotherapy and/or radiotherapy
PHASE 2:
ARM 1:
INCLUSION CRITERIA
- Female
- Age: 30 years and older
- A. Asymptomatic women who are scheduled to undergo routine screening mammography or routine screening mammography and US Or B. Subjects scheduled for image-guided needle biopsy as a result of findings obtained during standard of care imaging modalities (mammography, ultrasound and/or MRI).
5. Women whose most recent prior mammogram was interpreted as heterogeneously dense (ACR BI-RADS Breast Density C) or extremely dense (ACR BI-RADS Breast Density D).
EXCLUSION CRITERIA:
- Subjects who have had a Mammography and/or US and/or MRI examination performed on the day of the study prior to MIRA scan
- Subjects scheduled for a diagnostic mammography due to a suspicious lump
- Subjects who had undergone mastectomy and/or breast reconstruction
- Subjects who have undergone breast reduction or breast augmentation.
- Subjects who have large breast scar / breast deformation.
- Subjects who have significant existing breast trauma.
- Subjects who have undergone lumpectomy
- Subjects who have had a breast needle biopsy performed throughout the 6 weeks preceding the study
- Subjects with implanted pacemaker/defibrillator, implanted venous access device (portacath) or other implanted devices in the chest area
- Subjects with known Raynaud's Disease.
- Subjects who have a fever on the day of the MIRA imaging
- Subjects who are pregnant
- Subjects who are breast-feeding
- Subjects with known Mastitis
- Subjects who are currently undergoing chemotherapy and/or radiotherapy
- Subjects with contraindication to bilateral mammography or MRI.
- Subjects who participated in the Calibration Phase will not be able to participate in the Testing Phase.
- Subjects currently participating in another clinical study.
- Subjects who are unable to read, understand and execute written informed consent
ARM 2:
INCLUSION CRITERIA:
- Female
- Age: 30 years and older
- Asymptomatic women who are scheduled to undergo routine screening mammography or routine screening mammography and US
EXCLUSION CRITERIA :
- Subjects who have had a Mammography examination performed on the day of the study prior to MIRA scan
- Subjects scheduled for a diagnostic mammography due to a suspicious lump
- Subjects who have had a breast biopsy performed throughout the 6 weeks preceding the study
- Subjects who have a fever on the day of the MIRA imaging
- Subjects who are pregnant
- Subjects who are breast-feeding
- Subjects with known Mastitis
- Subjects with known Raynaud's Disease.
- Subjects who are currently undergoing chemotherapy and/or radiotherapy
- Subjects with contraindication to bilateral mammography
- Subjects who participated in the Calibration Phase will not be able to participate in the Testing Phase.
- Subjects currently participating in another clinical study.
- Subjects who are unable to read, understand and execute written informed consent
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Screening
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Arm 1
Testing phase (Phase II) Arm 1 - 180 participant will be enrolled for this arm. Participants will be enrolled to undergo MIRA device imaging. Following the MIRA device imaging procedure, the optimized risk model will assign a binary result to the participant. All participants will recive standart of care, participants with negative screening exams and a positive MIRA device imaging result will additionally undergo MRI. |
MIRA device imaging for adjunctive detection of breast cancer.
Arm 1 administarte result
Other Names:
|
Experimental: Arm 2
Testing phase (Phase II) Arm 2 - 150 participant will be enrolled for this arm.
Participants will be enrolled to undergo MIRA device imaging.
Following the MIRA device imaging procedure all participants in arm 2 will be following standard of care, MIRA device imaging will NOT change their clinical path.
|
MIRA device imaging for adjunctive detection of breast cancer.
Arm 1 administarte result
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Sufficient number of cancer case and controls have been imaged
Time Frame: up to 24 months
|
As this is a data collection study, end point will be reached when approximately 50 women with breast cancer and 100 healthy women (controls) are imaged by the device and sufficient for the comparison statistical analysis.
|
up to 24 months
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Miri Sklair-Levy, MD, The Chaim Sheba Medical Center at Tel-Hashomer
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Other Study ID Numbers
- 960-CSP-ISR_ImplantsMC_ILS3
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Breast Cancer
-
Rutgers, The State University of New JerseyNational Cancer Institute (NCI); Rutgers Cancer Institute of New JerseyActive, not recruitingStage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative Breast CancerUnited States
-
University of Southern CaliforniaNational Cancer Institute (NCI)TerminatedMale Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast CancerUnited States
-
University of WashingtonTerminatedBreast Cancer | Breast Cancer Stage I | Breast Cancer Stage II | Breast Cancer Stage III | Breast Cancer Stage IIB | Breast Cancer Stage IIA | Breast Cancer Stage IIIA | Breast Cancer Stage IIIB | Breast Cancer Stage IIIcUnited States
-
CelgeneCompletedBreast Cancer | Metastatic Breast Cancer | Stage IV Breast Cancer | Triple-negative Breast Cancer | Recurrent Breast Cancer | Breast Tumor | Cancer of the Breast | Triple-negative Metastatic Breast Cancer | Estrogen Receptor- Negative Breast Cancer | HER2- Negative Breast Cancer | Progesterone Receptor- Negative...United States, United Kingdom, Italy, Germany, Spain, Canada, Portugal, Australia, Austria, Greece, Brazil, France
-
University of Southern CaliforniaNational Cancer Institute (NCI)TerminatedHER2-positive Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast CancerUnited States
-
University of WashingtonNational Cancer Institute (NCI)CompletedHER2-positive Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Estrogen Receptor-negative Breast Cancer | Estrogen Receptor-positive Breast Cancer | Progesterone Receptor-negative Breast Cancer | Progesterone Receptor-positive Breast...United States
-
University of WashingtonNational Cancer Institute (NCI)CompletedHER2-positive Breast Cancer | Male Breast Cancer | Stage IV Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast CancerUnited States
-
Sidney Kimmel Cancer Center at Thomas Jefferson...Susan G. Komen Breast Cancer FoundationCompletedStage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative Breast CancerUnited States
-
Northwestern UniversityEisai Inc.UnknownMale Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Triple-negative Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative...United States
-
Ohio State University Comprehensive Cancer CenterCompletedStage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IIA Breast Cancer | Stage IIB Breast Cancer | Stage IIIC Breast Cancer | Stage III Breast CancerUnited States
Clinical Trials on MIRA device imaging
-
Real Imaging Ltd.Terminated
-
Real Imaging Ltd.Unknown
-
Real Imaging Ltd.Unknown
-
Ottawa Fertility CentreQuanovate Tech Inc.Not yet recruiting
-
Region MidtJylland DenmarkAarhus County, DenmarkTerminatedMusculoskeletal PainDenmark
-
Boninger, Michael, MDNational Institute of Neurological Disorders and Stroke (NINDS); Ripple Therapeutics...RecruitingAmputation | Amputation; Traumatic, HandUnited States
-
NYU Langone HealthNational Eye Institute (NEI)CompletedGlaucoma | Eye Diseases | Age-Related Macular Degeneration | Diabetic Retinopathy | Central Serous Chorioretinopathy | Glaucoma, SuspectUnited States
-
Sheffield Children's NHS Foundation TrustCompleted
-
Celal Bayar UniversityRecruiting
-
MolecuLight Inc.Completed